Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 March, 2018 19:40 IST
Alembic Pharma gets USFDA's tentative nod for Vilazodone HCl tablets
Source: IRIS | 19 Apr, 2017, 11.14AM
Comments  |  Post Comment

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Vilazodone Hydrochloride Tablets, 10mg, 20mg and 40mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Viibryd Tablets, 10 mg, 20mg and 40mg, of Forest Labs LLC. Vilazodone Hydrochloride Tablets are indicated for the treatment of Major Depressive Disorder (MDD). Alembic is currently in litigation with Forest Labs LLC in District Court of Delaware and has stipulated to stay the case in view of the ongoing settlement discussions.

Vilazodone Hydrochloride Tablets have an estimated market size of USD 340 million for twelve months ending December 2016 according to IMS.

Alembic now has a total of 54 ANDA approvals (47 final approvals and 7 tentative approvals) from the USFDA.

Shares of the company gained Rs 12, or 1.97%, to trade at Rs 621.95. The total volume of shares traded was 7,783 at the BSE (11.05 a.m., Wednesday).

Alembic Pharmaceuticals Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Suven Life Sciences secures 3 overseas product patents - 22-Mar-2018 12:24
Cox & Kings sells 11.58% stake in subsidiary - 22-Mar-2018 12:20
Sadbhav Infra receives LoA for NHAI road project - 22-Mar-2018 10:44
Steel Strips Wheels receives 7,000 wheel order from UK aftermarket - 22-Mar-2018 10:37
Zensar Technologies acquires US based Cynosure Inc - 22-Mar-2018 10:33
Dilip Buildcon declared L-1 bidder for Rs 6.77 bn NHAI project - 22-Mar-2018 10:26
IRB Infrastructure Developers wins Rs 34 bn Hapur bypass BOT project - 22-Mar-2018 10:18
Sun Pharma announces USFDA approval of ILUMYA drug - 22-Mar-2018 09:39
Ashok Leyland bags orders for 2,100 buses from Tamil Nadu - 21-Mar-2018 10:17
Suzlon designs and produces India's longest wind turbine blade - 21-Mar-2018 10:11
Non-banks to drive MSME credit growth; asset quality a key monitorable: ICRA - 21-Mar-2018 10:06
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer